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Background. The Strategic Timing of AntiRetroviral Treatment (START) trial demonstrated that immediate (at CD4+ >500 
cells/µL) vs deferred (to CD4+ <350 cells/µL or AIDS) antiretroviral therapy (ART) initiation reduced risk for AIDS and serious 
non-AIDS (SNA). We investigated associations of inflammation, coagulation, and vascular injury biomarkers with AIDS, SNA or 
death, and the effect of immediate ART initiation.
Methods. Biomarkers were measured from stored plasma prior to randomization and at month 8. Associations of baseline bio-
markers with event risk were estimated with Cox regression, pooled across groups, adjusted for age, gender, and treatment group, 
and stratified by region. Mean changes over 8 months were estimated and compared between the immediate and deferred ART arms 
using analysis of covariance models, adjusted for levels at entry.
Results. Baseline biomarker levels were available for 4299 START participants (92%). Mean follow-up was 3.2 years. Higher lev-
els of IL-6 and D-dimer were the only biomarkers associated with risk for AIDS, SNA or death, as well as the individual components 
of SNA and AIDS events (HRs ranged 1.37–1.41 per 2-fold higher level), even after adjustment for baseline CD4+ count, HIV RNA 
level, and other biomarkers. At month 8, biomarker levels were lower in the immediate arm by 12%–21%.
Conclusions. These data, combined with evidence from prior biomarker studies, demonstrate that IL-6 and D-dimer consist-
ently predict clinical risk across a broad spectrum of CD4 counts for those both ART-naïve and treated. Research is needed to iden-
tify disease-modifying treatments that target inflammation beyond the effects of ART.
Keywords. coagulation; comorbidities; end-organ disease; HIV disease; inflammation risk. 
Effective antiretroviral therapy (ART) has prolonged survival 
and shifted the morbidity spectrum for HIV+ persons away 
from AIDS and toward serious non-AIDS (SNA)-defining 
conditions, including cardiovascular disease, cancer, and other 
end-organ diseases [1, 2]. A key factor contributing to excess 
SNA event risk among HIV+ patients includes persistent 
abnormalities in systemic inflammation and coagulation [3–8]. 
Based on data from earlier large randomized trials, we and oth-
ers have demonstrated that plasma measures of inflammation 
and/or coagulation activation predict risk for cardiovascular 
disease (CVD) [6, 9, 10], cancer [7], and all-cause mortality 
[3, 11–13], along with the composite of SNA [8, 14]. These data 
include patients with advanced HIV disease and/or those with 
low nadir CD4+ counts. It remains unclear whether ongoing 
inflammation is associated with clinical event risk specifically 
among HIV+ patients with recent diagnosis and preserved 
immunity (ie, CD4+ counts >500 cells/µL).
Inflammation may improve with ART, but biomarker levels 
continue to be abnormal among ART-treated patients with viral 
suppression when compared with uninfected controls [4, 15, 
16]. Early HIV diagnosis and early initiation of ART is now the 
goal for management of HIV infection in much of the world. 
Importantly, prior data characterizing the effect of ART on 
levels of inflammatory biomarkers typically involve nonrand-
omized comparisons, lack of a comparison group not receiving 
ART, and/or participants with low CD4+ counts [15, 17–21].
The International Network for Strategic Initiatives in Global 
HIV Trials (INSIGHT) Strategic Timing of AntiRetroviral 
Treatment (START) trial randomized 4684 ART-naïve HIV+ 
persons with CD4+ counts >500 cells/µL to initiate ART imme-
diately after randomization, vs deferring ART until a CD4+ 
count of <350 cells/µL or progression to AIDS. In START, 
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immediate ART initiation led to a 57% reduction in a com-
posite outcome of AIDS and SNA nonfatal events or deaths; 
reductions in the risk of AIDS and SNA events were 72% and 
39%, respectively [22]. START represents a global HIV+ popu-
lation, and 68% of the primary end points in START occurred 
among participants with CD4+ counts >500 cells/µL [22]. The 
START trial provides a unique opportunity to study associa-
tions between biomarkers of inflammation, coagulation, and 
vascular injury with major clinical outcomes among patients 
with relative immune preservation.
METHODS
Study Design and Clinical Data Collection
The design and primary findings from the START trial have 
been described [22]. All participants provided written informed 
consent. We used specimens from study visits that occurred 
prior to randomization (defined as “baseline”) and at month 8, 
and included events that occurred through May 26, 2015, when 
the trial results were unblinded.
All clinical events and deaths in START were reviewed and 
adjudicated by an end point committee blinded to treatment 
assignment using pre-established criteria [22]. AIDS was defined 
as serious events within the 1993 expanded surveillance docu-
ment of the Centers for Disease Control and Prevention, but also 
including Hodgkin lymphoma and excluding nonfatal Herpes 
simplex virus infection and esophageal candidiasis (excluded 
because of their lesser severity). SNA-related events consisted of 
any of the following conditions: cardiovascular disease (CVD; 
myocardial infarction, stroke, or coronary revascularization) or 
death from CVD; end-stage renal disease (initiation of dialysis or 
renal transplantation) or death from renal disease; liver disease 
(decompensated) or death from liver disease; non-AIDS-defin-
ing cancer (except for basal cell or squamous cell skin cancer) or 
death from cancer; and any other death not attributable to AIDS 
(see the Appendix of the primary START manuscript) [22].
Plasma Biomarkers
Using plasma collected at baseline and the month 8 visit, which 
was stored centrally at –70°C, 7 plasma biomarkers were meas-
ured that reflected systemic inflammation (IL-6, high-sensitiv-
ity C-reactive protein [hsCRP] and serum amyloid A [SAA]), 
vascular inflammation (soluble intercellular adhesion mole-
cule-1 [sICAM] and vascular adhesion molecule-1 [sVCAM]), 
immune activation (interleukin-27 [IL-27]), and coagulation 
activation (D-dimer). IL-6 was measured using high-sensitivity 
enzyme-linked immunosorbent assay (R&D Systems), D-dimer 
using the VIDAS system (BioMerieux), and IL-27 using immu-
noassay (MesoScale). A multiplex platform was used to meas-
ure hsCRP, SAA, sICAM, and sVCAM (Vascular Injury II Panel, 
MesoScale). All samples were analyzed by researchers blinded 
to treatment group.
Statistical Analyses
Biomarkers were analyzed either on the log2 scale or using rank-
based methods because biomarker distributions were right-
skewed, and close to normal after log transformation; also, 
model assumptions were usually better satisfied for log-trans-
formed biomarkers compared with no transformation.
Associations of baseline biomarker levels (log2 scale) with 
event risk (serious AIDS, SNA, all-cause mortality, and their 
composite) were estimated with Cox proportional hazards 
regression models, pooled across treatment groups, separately 
for each biomarker. We pooled the treatment groups because 
tests for heterogeneity showed that the associations between 
biomarkers and the risk of the primary outcome were similar 
in the immediate and the deferred ART groups for all 7 bio-
markers. In addition, the homogeneity of the associations 
between biomarkers and clinical events was assessed across age 
and gender. The Cox models were adjusted for age, gender, and 
treatment group and stratified by region. Additional adjustment 
considered baseline HIV RNA level and CD4+ count given 
the importance for clinical risk. Biomarker associations with 
events were also assessed in models that contained all 7 bio-
markers. The proportional hazards assumption was examined 
with expanded Cox models that included an interaction term 
for the biomarker and log failure time. Kaplan-Meier estimates 
of the cumulative proportion of participants with clinical events 
were computed in 2 ways, (1) pooled over treatment groups, by 
quartiles of baseline D-dimer and IL-6 levels, and (2) separately 
for the immediate and deferred groups, by whether the baseline 
biomarker level was above or below the median. In all analy-
ses, follow-up was censored on May 26, 2015, or the date of last 
study contact.
Spearman’s rank correlation coefficients were computed 
between baseline levels of biomarkers, as well as between base-
line factors (age, gender, CD4+ and CD8+ cell count, plasma 
HIV RNA level, body mass index [BMI], smoking status, and 
time since HIV diagnosis) and baseline biomarker levels.
Mean changes in biomarker levels (log2 scale) from baseline 
to the month 8 visit were compared between the immediate and 
deferred ART arms by intent to treat using analysis of covari-
ance (ANCOVA) models, adjusted for baseline biomarker 
levels. Mean changes were back-transformed and presented 
as percent change on the original biomarker scale. Similar 
ANCOVA models were used for subgroup analyses by CD4+ 
and CD8+ cell counts and HIV RNA at baseline; homogeneity 
of the immediate vs deferred treatment difference across sub-
group variables was assessed by testing for interaction between 
the treatment group indicator and the subgroup variable.
Statistical analyses were performed using SAS software, ver-
sion 9.3 (SAS Institute Inc., Cary NC), and R software, version 
3.3 (R Foundation for Statistical Computing, Vienna, Austria). 
P values ≤0.05 were considered significant.
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RESULTS
Participant Characteristics and Biomarker Levels at Baseline (Prior to 
Randomization)
The START trial enrolled 4684 HIV+ participants from 215 
sites in 35 countries, and 4487 (96%) consented to store plasma. 
Among the 4299 (92% of START) participants with available 
stored plasma samples who had baseline biomarker determina-
tions for at least 1 of the 7 biomarkers (Figure 1), the median 
age was 36 years; 27% were female (Table 1). Self-reported race/
ethnicity reflects global enrollment from the United States 
(11%), South America and Mexico (24%), Europe and Israel 
(40%), Australia (2%%), Africa (21%), and Asia (8%). The 
median CD4+ count and HIV viral load at entry were 651 cells/
µL and 12 911 copies/mL, respectively; the median time since 
HIV diagnosis was 1.0  year (interquartile range [IQR], 0.4–
3.0 years). The mean follow-up time was 3.2 years.
Baseline biomarker levels were moderately correlated with one 
another (r ≥ 0.2; P < 0.0001) for all combinations except for any 
biomarkers with IL-27, and correlations of sVCAM with D-dimer 
and IL-6, or sICAM with D-dimer. The strongest correlations were 
between sICAM and sVCAM (r = 0.75), and hsCRP with SAA 
(r = 0.68) or IL-6 (r = 0.51). At baseline, higher levels of all 7 bio-
markers were associated with higher HIV RNA level and CD8+ 
counts, but not lower CD4+ counts (Supplemental Figure A).
ART Use and CD4+ Cell Counts
All 4299 participants were naïve to ART at baseline (as specified 
by START eligibility criteria). ART was used for 94% and 29% 
of follow-up time in the immediate and deferred ART groups, 
respectively. Through all follow-up, the average CD4+ count 
increased in the immediate group by 173 cells/µL (95% con-
fidence interval [CI], 164–183) and decreased in the deferred 
group by 20 cells/µL (95% CI, 10–29), for a difference of 193 
cells/µL (95% CI, 184–203) between groups.
Among the 3980 participants for whom baseline to month 
8 biomarker changes were assessed, 1941 (98%) participants 
in the immediate ART group and 163 (8%) in the deferred 
group had initiated ART by 8 months. ART had been used for 
91% and 4% of time between baseline and month 8 among the 
immediate and deferred ART groups, respectively. By month 8, 
the average CD4+ cell count had increased from baseline in the 
immediate group by 91 cells/µL and decreased by 76 cells/µL in 
the deferred group. Among the immediate group participants 
who initiated therapy by month 8, ART included tenofovir dis-
oproxil fumarate (TDF) for 89%, efavirenz (EFV) for 73%, a 
ritonavir-boosted protease inhibitor (PI) for 18%, and an inte-
grase strand transfer inhibitor (INSTI) for 4%.
Associations of Baseline Biomarker Levels With Clinical Event Risk
Primary events (AIDS, SNA, or death) were experienced by 129 
participants, 40 in the immediate and 89 in the deferred ART 
groups; 57 experienced fatal or nonfatal AIDS events (23 tuber-
culosis [TB]) and 74 SNA events or non-AIDS deaths; 50 expe-
rienced cancer (AIDS or non-AIDS; 12 Kaposi’s sarcoma) and 
24 CVD. Participants with, compared with without, a primary 
event had higher median biomarker levels at baseline (Table 1).
Figure 2 presents event risk over follow-up as predicted by 
baseline biomarker levels. Higher levels of D-dimer and IL-6 
were associated with increased risk for the primary composite 
of AIDS, SNA, or death, as well as the individual components of 
SNA or non-AIDS death and AIDS (fatal or nonfatal). Risk for 
AIDS events was also associated with higher SAA and sICAM 
levels, and hsCRP approached significance (P = .053). D-dimer 
and IL-6 associations with AIDS, SNA, or death persisted after 
additional adjustment for baseline CD4+ count and HIV RNA 
level (HR, 1.36 per 2× higher D-dimer; 95% CI, 1.11–1.66; HR, 
1.35 per 2× higher IL-6; 95% CI, 1.12–1.62). When considering 
models that included baseline levels of all 7 biomarkers jointly, 
along with age, gender, and treatment group, risk for AIDS, 
SNA, or death was significantly associated with IL-6 (HR, 1.34 
per 2× higher IL-6 levels; 95% CI, 1.08–1.67) and D-dimer (HR, 
1.32 per 2× higher D-dimer levels; 95% CI, 1.07–1.63), but none 
of the other biomarkers.
Figure  3A presents Kaplan-Meier estimates for the cumu-
lative percentage of participants experiencing AIDS and SNA 
events by quartiles of the baseline levels of IL-6 or D-dimer. 
The associations for IL-6 and D-dimer were stronger for events 
that occurred more proximal to the biomarker measurements 
(P values for interaction with log follow-up time were 0.008 
for D-dimer and 0.016 for IL-6). This change in event rates 
over time was more pronounced in the deferred arm for IL-6 
2124 with ≥1
baseline biomarker  
4684 HIV-positive adults with
CD4+ cell counts >500 cells/µL
Immediate ART group
(n = 2325)
Deferred ART group
N=2359
2175 with ≥1
baseline biomarker   
1975 with ≥1
baseline and
month 8 biomarker
2005 with ≥1
baseline and
month 8 biomarker   
Total
sample
(n = 4299*)
Total
sample
(n = 3980*)
* Of 4487 participants who consented to storing specimens for future research.Of the 319 participants
(149 in the immediate group and 170 in the deferred group) who had biomarker data at baseline but
not month 8, 7 had died and 44 were lost to follow-up prior to month 8, 145 missed the month 8 visit,
65 attended the visit but no specimen was collected, and for 59 participants the specimen could not be
analyzed. The distribution of reasons was similar in the immediate and deferred groups.   
Figure  1. Flow diagram for availability of biomarker data among START par-
ticipants. *Of 4487 participants who consented to storing specimens for future 
research. Of the 319 participants (149 in the immediate group and 170 in the 
deferred group) who had biomarker data at baseline but not month 8, 7 had died 
and 44 were lost to follow-up prior to month 8, 145 missed the month 8 visit, 65 
attended the visit but no specimen was collected, and for 59 participants the speci-
men could not be analyzed. The distribution of reasons was similar in the immediate 
and deferred groups.
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(P  =  0.005 for interaction with log time in the deferred arm, 
P = 0.70 in the immediate arm), but the relationship was con-
sistent across both treatment arms for D-dimer.
Associations of IL-6 and D-dimer with the risk of AIDS, 
SNA, or death were similar across treatment groups (P = 0.96 
and P = 0.97, respectively, for interaction). This is illustrated in 
Figure 3B, which presents the cumulative percentage of partic-
ipants experiencing the primary composite within the imme-
diate and deferred ART groups in START, separately for those 
with above- or below-median IL-6 and D-dimer levels at base-
line. This figure shows that the relative difference in event risk 
between high and low biomarker levels is similar for both the 
immediate and deferred groups, even though the event rate for 
the deferred group is higher than the event rate for the imme-
diate group for both biomarkers. For example, in the immedi-
ate group, the cumulative event rates at month 36 were 2.2% 
and 0.8% for those whose baseline D-dimer was above or below 
the median, respectively (a ratio of 2.75); corresponding rates 
for the deferred group were 5.4% and 2.3% (a ratio of 2.35) 
(Figure 3B).
Changes in Biomarkers From Baseline to Month 8 With Immediate vs 
Deferred ART
In the immediate group (ART initiated at baseline), levels of IL-6, 
D-dimer, SAA, IL-27, sICAM, and sVCAM declined between 
baseline and month 8 (Figure 4). D-dimer levels increased by 
month 8 in the deferred ART group, and hsCRP increased in both 
the immediate and the deferred groups. Levels of D-dimer, IL-6, 
SAA, sICAM, and sVCAM declined from baseline to month 8 
by 12%–21% more in the immediate group compared with the 
deferred group (P < .001 for each biomarker) (Figure 4). These 
differences persisted, with slightly larger magnitudes, when 
excluding deferred group participants who started ART prior 
to month 8 (data not shown). The ART-associated declines 
in biomarker levels at 8  months (eg, 19.1% for D-dimer and 
11.6% for IL-6) are modest in absolute terms (Supplementary 
Table A); median D-dimer levels within the immediate 
Table 1. Baseline Characteristics in START, Overall and According to Primary Event Status (n = 4299)
Median [IQR], n (%)
P ValuebOverall Primary Eventa No Primary Eventa
Participants 4299 129 4170
Demographics
Age, y 36 [29–44] 44 [34–51] 36 [29–44] <0.001
Female gender 1141 (26.5) 27 (20.9) 1114 (26.7) 0.14
Race 0.042
Black 1301 (30.3) 41 (31.8) 1260 (30.2)
White 1938 (45.1) 68 (52.7) 1870 (44.8)
Other 1060 (24.7) 20 (15.5) 1040 (24.9)
Medical history
Duration of HIV diagnosis, y 1.0 [0.4–3.0] 1.2 [0.5–3.6] 1.0 [0.4–3.0] 0.34
CD4,c cells/µL 651 [584–765] 632 [584–742] 651 [584–765] 0.26
CD8+, cells/µL 1040 [775–1399] 1081 [799–1505] 1040 [774–1395] 0.12
CD4:CD8 ratio 0.66 [0.48–0.89] 0.61 [0.42–0.82] 0.66 [0.48–0.89] 0.031
HIV RNA, copies/mL 12 911 [3120–43 730] 22 726 [7485–63 956] 12 647 [3057–42 889] 0.001
Hepatitis B/C 276 (6.5) 10 (7.8) 266 (6.5) 0.54
Prior CVDd 25 (0.6) 3 (2.3) 22 (0.5) 0.04
BMI, kg/m2 24.5 [22.1–27.8] 24.6 [22.5–27.7] 24.5 [22.1–27.8] 0.66
Current smoking 1398 (32.5) 57 (44.2) 1341 (32.2) 0.004
Biomarkers
D-Dimer, μg/mL 0.33 [0.23–0.50] 0.40 [0.29–0.66] 0.32 [0.22–0.49] <0.001
IL-6, pg/mL 1.39 [0.97–2.12] 1.65 [1.26–2.57] 1.38 [0.96–2.11] <0.001
hsCRP, μg/mL 1.71 [0.74–4.01] 1.89 [0.93–4.54] 1.69 [0.73–3.97] 0.07
SAA, mg/L 4.52 [2.53–8.75] 5.68 [3.15–9.77] 4.47 [2.51–8.74] 0.014
IL-27, pg/mL 251 [126–520] 261 [118–506] 251 [126–521] 0.97
sICAM, μg/mL 541 [423–693] 622 [502–751] 538 [422–691] <0.001
sVCAM, μg/mL 722 [62–922] 808 [28–987] 720 [61–919] 0.004
Abbreviations: BMI = body mass index; CVD = cardiovascular disease; hsCRP = high-sensitivity C-reactive protein; IL = interleukin; IQR: interquartile range; MI = myocardial infarction; 
SAA = Serum Amyloid A; sICAM = soluble intercellular adhesion molecule; SNA = serious non-AIDS events, sVCAM = soluble vascular cellular adhesion.
aPrimary event refers to the composite study end point of AIDS, SNA, or death.
bP value comparing those with a primary event with those without a primary event. Medians were compared using Wilcoxon rank-sum tests and proportions compared using chi-square 
tests. The Fisher exact test was used for comparison of prior CVD risk.
cAverage of screening and baseline values.
dMI, coronary revascularization, or stroke.
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ART group were 0.32  μg/mL at baseline and 0.28  μg/mL 
at month 8, and corresponding values for IL-6 were 1.41 pg/mL 
and 1.27 pg/mL.
We carried out subgroup analyses to determine whether 
the immediate vs deferred treatment difference in biomarker 
changes was homogeneous across baseline levels of CD4+, 
CD8+, and HIV RNA (Supplemental Tables B, C, D). For all 
biomarkers, the treatment difference varied across HIV RNA 
levels (except for IL-27) and CD8+ count (except for SAA), and 
participants with higher HIV RNA levels at baseline demon-
strated the greatest ART-associated declines in the immediate 
group and the greatest increases in the deferred group (except 
for IL-27) over 8 months. Specifically, among persons with HIV 
RNA levels ≥30 000 copies/mL at entry, D-dimer levels declined 
by 21% in the immediate group, but actually increased by 8% in 
the deferred group; corresponding changes for IL-6 levels were 
a 14% decline and a 12% increase, respectively.
DISCUSSION
In a large randomized clinical trial (START) of HIV+ patients 
who were early in the course of disease and had preserved 
immunity, we report the associations of biomarker levels of sys-
temic inflammation, coagulation, and vascular injury with risk 
for clinical events, and the effect of immediate vs deferred ART 
initiation on these same biomarkers. Greater systemic inflam-
mation (ie, IL-6 levels) and coagulation activity (ie, D-dimer 
levels) at entry in START were associated with increased risk 
for AIDS events, SNA events, and the composite of AIDS, 
SNA, or death. The detrimental effect of inflammation and/or 
coagulation activation was present in both the immediate and 
deferred ART groups in START (ie, were independent of the 
timing of ART initiation), and demonstrated similar associa-
tions for AIDS and SNA events when examined separately. In 
randomized comparisons of immediate and deferred ART ini-
tiation, immediate treatment led to significant reductions over 
8 months in D-dimer, IL-6, SAA, sICAM, and sVCAM levels, 
both in absolute terms and relative to deferral of ART.
It is well established that HIV infection is associated with ele-
vations in systemic inflammatory markers, cytokines, and circu-
lating vascular adhesion molecules [4, 23, 24]. Consistent with 
this, we report median levels of IL-6 (1.39 pg/mL) and D-dimer 
(0.33 μg/mL) at entry in START that are higher than levels previ-
ously reported among populations of HIV-negative participants 
(1.23 pg/mL and 0.22 μg/mL, respectively, in the Multi-Ethnic 
Study of Atherosclerosis; median age, 60  years) [4]. In other 
studies, ART treatment has also been shown to decrease lev-
els of D-dimer, IL-6, and sVCAM [15, 17, 24–26], though the 
degree of decrease may vary by ART regimen [17] and ART-
induced viral suppression may not fully restore levels of these 
biomarkers to those of age-adjusted controls [4, 15, 23, 24]. 
Specifically, when compared with levels among uninfected indi-
viduals, IL-6 and D-dimer remain approximately 40%–75% higher 
among HIV+ patients on ART with viral suppression [4, 27]. 
We show that immediate ART initiation reduced levels of 
D-dimer, IL-6, SAA, sICAM, and sVCAM, even when started 
early in the course of HIV disease, before a clinically significant 
AIDS, SNA, or Death
(129 events)
AIDS or AIDS Death
(57 events)
SNA or non-AIDS Death
(74 events)
D-dimer
IL-6
hsCRP
SAA
IL-27
sICAM
sVCAM
0.5 0.75 1 2 3 0.5 0.75 1 2 3 0.5 0.75 1 2 3
1.13
1.23
1.01
1.13
1.08
1.39
1.41 1.52
1.46
1.15
1.17
1.10
1.66
1.39 0.98
1.05
0.97
1.12
1.06
1.41
1.37
Figure 2. Hazard ratios (HRs) with 95% confidence intervals (CIs) for the risk of clinical events associated with 2× higher baseline biomarker levels in START (n = 4299). 
HRs were estimated in separate proportional hazards models, pooled across treatment groups, adjusted for age, gender, and treatment group, and stratified by geographic 
location. HRs are per 2× higher biomarker(s). Biomarker associations with event risk were homogeneous across treatment groups, except for sVCAM with AIDS (higher HR in 
the deferred group) and sICAM with SNA (higher HR in the immediate group). Abbreviations: IL = interleukin; hsCRP = high-sensitivity C-reactive protein; SAA = serum amyloid 
A; sICAM = soluble intercellular adhesion molecule; sVCAM = soluble vascular cellular adhesion molecule.
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Figure 3. Kaplan-Meier (KM) estimates for the cumulative percentage of participants experiencing AIDS, serious non-AIDS, or death in START (4299). (A) Kaplan-Meier 
estimates for the cumulative percentage of participants experiencing an AIDS or AIDS-death (top row) and serious non-AIDS or non-AIDS death (bottom row) pooled over 
study groups by quartiles of D-dimer and IL-6 at baseline (first quartile = blue; second quartile = green; third quartile = orange; fourth quartile = red). The number at risk at 
each year of follow-up is presented below the x-axis. (B) Kaplan-Meier estimates for the cumulative percentage of participants experiencing the composite outcome of AIDS, 
serious non-AIDS or death in the immediate (red lines) and deferred (blue lines) ART groups in START, separately by whether baseline level of D-dimer and IL-6 were above 
(solid lines) or below (dashed lines) their median at baseline.
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decline in CD4+ count has occurred. When compared with the 
effect of ART initiation (vs deferral) among a subset of partic-
ipants in the SMART trial who were not using ART at entry 
(prior to initiating ART: median CD4+ count, 447 cells/mm3; 
HIV RNA, 39 810 copies/mL), we report here a smaller reduc-
tion of D-dimer levels in START (31% vs 19%, respectively), 
but a similar reduction for IL-6 levels (13% vs 12%, respectively, 
though ART-related IL-6 changes did not reach significance in 
the smaller subset of SMART) [15]. Finally, we reported a par-
adoxical increase in hsCRP levels with ART treatment, but this 
lack of a decline (or an increase) has been previously described 
and may be the result of improved hepatocyte synthetic function 
(ie, improved hsCRP release), which was previously impaired in 
the context of untreated HIV infection [15, 17, 28–31].
Our findings on clinical risk prediction add to recent literature 
that has reshaped our current understanding of the mechanisms 
contributing to morbidity and mortality during HIV disease in 
the current era. Notably, measures of systemic inflammation are 
consistently associated with risk for SNA events and the devel-
opment of individual end-organ diseases [6, 7, 32–35]. Recent 
data have also suggested that the independent contribution of 
CD4+ counts to CVD and other SNA event risk may be more 
modest, or not apparent, at higher CD4+ counts [22, 36]. This 
may explain why we did not detect a significant association with 
clinical risk for IL-27, which is produced by antigen-presenting 
cells and is important in T-cell immune responses. We have 
previously reported that among 3766 ART-treated and virolog-
ically suppressed HIV+ patients, risk for SNA events or death 
was associated with elevations in IL-6 and D-dimer (HR, 1.45 
for IL-6 and 1.28 D-dimer level, per 2× higher biomarker level, 
respectively) [8]. Even though the START study population 
included only untreated participants with higher CD4+ counts 
at entry, we estimate similar HRs for SNA event risk (HR, 1.41 
for IL-6 and 1.37 for D-dimer). We also show that the adverse 
effects from systemic inflammation, in terms of clinical risk 
over the long term, are present for HIV+ patients whether they 
start ART very early or later in their disease course (ie, both 
treatment groups in START). Additional follow-up is required 
in START to accurately estimate biomarker associations with 
clinical event risk after viral suppression is achieved among this 
population treated at higher CD4+ counts, especially given our 
initial observation that biomarker associations were stronger 
for early vs later events in START.
Important questions remain regarding the underlying patho-
genesis driving chronic inflammation and coagulation activity 
among HIV+ patients, both before and after ART initiation. 
Hypothesized mechanisms have been previously reviewed [37, 
38] and may involve factors related to persistence of HIV and 
related immune activation, incomplete immune recovery, loss of 
regulatory function, transcription of defective proviruses [39], 
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reduced control of copathogens (eg, cytomegalovirus), injury 
to mucosal surfaces with translocation of microbial antigens, 
toxicity from ART, and host and lifestyle factors. We show that 
even among HIV+ patients who start ART very early in the 
course of disease, there is a subset of ART-treated patients with 
greater clinical risk; such patients might benefit from reduc-
ing ongoing inflammation whatever the underlying mecha-
nisms. A central focus and priority of current HIV research is 
to identify anti-inflammatory strategies and determine if that 
will translate into reductions in clinical risk for 1 or more SNA 
conditions [38]. Importantly, any candidate adjunct treatment 
intervention would need to establish safety (or entail minimal 
risk) and not compromise ART effectiveness, given the excel-
lent outcomes now experienced among HIV-positive patients 
treated early with ART.
Strengths of this study include the randomized design, large 
sample size, globally diverse study population, inclusion of 
HIV+ patients with preserved immunity initiating ART early 
(reflective of current goals for clinical practice), and the stand-
ardized ascertainment and adjudication of clinical events. 
Limitations include the lack of additional laboratory measures, 
the lack of functional measures that more directly reflect poten-
tial disease mechanisms, and the use of a single follow-up time 
point at 8  months that precluded determination of whether 
immediate vs deferred ART differences in biomarker levels per-
sisted after more prolonged viral suppression (eg, >2 years after 
ART initiation). Longer follow-up of START will help clarify 
whether the full effect of more sustained virologic suppression 
over years ultimately reverses the harmful effects of ART defer-
ral (reflected in the higher levels of inflammation and coagu-
lation biomarkers), when compared with immediate ART 
treatment at higher CD4+ counts. The relatively low number of 
events in START overall, and in the immediate ART group in 
particular, precluded reliable estimates of (a) event risk among 
any individual end-organ disease condition or focused com-
posite, (b) event risk after viral suppression was achieved and 
biomarkers reached their new set points, and (c) the interaction 
between biomarkers and treatment group or follow-up time. 
Finally, participants in clinical trials may have greater adher-
ence and health-seeking behaviors, which may impact the gen-
eralizability of results.
In START, among a global population of HIV+ persons 
with preserved immunity, immediate ART initiation reduced 
biomarker levels of systemic inflammation, coagulation, and 
vascular injury compared with ART deferral. Differences in 
biomarkers between groups were the result of reductions after 
ART initiation, concurrent with increases among participants 
who deferred ART. Associations between IL-6 and D-dimer 
levels and risk for AIDS, SNA, and death were present for both 
treatment groups in START. When combined with data from 
prior studies [3, 6, 8, 10, 32, 40, 41], higher levels of IL-6 and 
D-dimer consistently predict increased clinical risk across a 
broad spectrum of CD4+ counts for HIV+ patients, both ART-
naïve and ART-treated. Cumulatively, these observations sup-
port the need for research to better understand the mechanisms 
driving ongoing inflammation and coagulation abnormalities 
during effectively treated HIV disease, and to identify dis-
ease-modifying treatments or lifestyle interventions that reduce 
inflammation beyond the effects of ART.
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